MedStar Georgetown proton center selects RayStation
The proton center at MedStar Georgetown University Hospital will utilize RayStation for planning on the MEVION S250i Proton Therapy System with HYPERSCAN when the facility opens for treatment later this year. The RayStation treatment planning system will enable the utilization of advanced IMPT capabilities that are unique to the HYPERSCAN technology, including multi-leaf collimation with Mevion’s Adaptive Aperture.
The combination of RayStation and Mevion’s HYPERSCAN technology will enable clinicians at MedStar Georgetown to plan and treat patients with the advantage of very sharp field edges and minimized radiation to critical structures.
Johan Löf, CEO of RaySearch, says: “The addition of support for HYPERSCAN in RayStation fits well with our commitment to supporting all modalities and vendors in the field of radiation therapy. With our ever-expanding toolset, we believe we are uniquely qualified and positioned to advance cancer treatment in order to improve outcomes for patients and support our customers and industry partners.”
Joe Jachinowski, CEO of Mevion Medical Systems, says: “Mevion is looking forward to working with MedStar Georgetown and RaySearch to implement HYPERSCAN technology clinically. Our collaboration with RaySearch has been very productive and we are excited that everything has come together as planned.”
About MedStar Georgetown University Hospital
Learn more at: https://www.medstargeorgetown.org/our-services/cancer-care/why-choose-us/proton-beam
About Mevion Medical Systems
Mevion Medical Systems, Inc. is a leading provider of proton therapy systems for use in radiation therapy for cancer. Mevion is based in Littleton, Massachusetts, US, with a presence in the Europe, Japan and China. Learn more at: www.mevion.com.
RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare, which comprises a new product area for RaySearch, and which will be launched in December 2017. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the share has been listed on Nasdaq Stockholm since November 2003.
More information about RaySearch is available at www.raysearchlabs.com
1 MEVION S250i Proton Therapy System with HYPERSCAN has not been cleared by the USFDA for clinical use.
2 Subject to regulatory clearance in some markets.
For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00